Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION trial)

American Journal of Cardiology

Volumn 95, Issue 11, 2005, Pages 1295-1301

  Madan, Mina ^a   Radhakrishnan, Shyam ^a   Reis, Marciano ^a   Paradiso Hardy, Fran L ^a   Godin Edgecombe, Maggie ^a   Sparling, Catherine ^a   Phillips, Anne Marie ^a   Shanmugasegaram, Shamila ^a   Fort, Stephen ^a   Naqvi, Salim Z ^a   Cohen, Eric A ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

ACUTE DISEASE; ADULT; AGED; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, ELECTIVE; THROMBOSIS; TREATMENT OUTCOME; TYROSINE;

EID: 21144439571     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.01.071     Document Type: Article

References (29)

1. E.M. Antman, M. Cohen, D. Radley, C. McCabe, J. Rush, J. Premmereur, E. Braunwald TIMI 11B (Thrombolysis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) Investigators Assessment of the treatment of enoxaparin for unstable angina/non-Q-wave myocardial infarction TIMI 11B-ESSENCE meta-analysis Circulation 100 1999 1602 1608
2. S.G. Goodman, D. Fitchett, P.W. Armstrong, M. Tan, A. Langer Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide Circulation 107 2003 238 244
3. M. Cohen, P. Theroux, S. Borzak, M.J. Frey, H.D. White, W. Van Mieghem, F. Senatore, J. Lis, R. Mukherjee, K. Harris, F. Bigonzi Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study The Antithrombotic Combination Using Tirofiban and Enoxaparin Am Heart J 144 2002 470 477
4. J.P. Collet, G. Montalescot, L. Lison, A. Choussat, A. Ankri, G. Drobinski, I. Sotirov, D. Thomas Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris Circulation 103 2001 658 663
5. R.A. Kadakia, S.R. Baimeedi, J.J. Ferguson Low-molecular-weight-heparins in the cardiac catheterization laboratory Tex Heart Inst J 31 2004 72 83
6. D.J. Kereiakes, C. Grines, E. Fry, P. Esente, D. Hoppensteadt, M. Midei, L. Barr, W. Matthai, M. Todd, T. Broderick NICE 1 and NICE 4 Investigators Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention The NICE 1 and NICE 4 Investigators J Invas Cardiol 13 2001 272 278
7. M.M. Rabah, J. Premmereur, M. Graham, J. Fareed, D.A. Hoppensteadt, L.L. Grines, C.L. Grines Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris Am J Cardiol 84 1999 1391 1395
8. The PRISM-PLUS Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
9. The PURSUIT Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with an acute coronary syndromes N Engl J Med 339 1998 436 443
10. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial Lancet 356 2000 2037 2044
11. E.J. Topol, D.J. Moliterno, H.C. Herrmann, E.R. Powers, C.L. Grines, D.J. Cohen, E.A. Cohen, M. Bertrand, F.J. Neumann, G.W. Stone TARGET Investigators Do tirofiban and ReoPro give similar efficacy trial: comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
12. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
13. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T.L. Schreiber, W.R. Bell, G. Knatterud, T.L. Robertson, M.L. Terrin Thrombolysis in Myocardial Infarction (TIMI) trial--phase 1: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
14. D.J. Kereiakes, G. Montalescot, E.M. Antman, M. Cohen, H. Darius, J.J. Ferguson, C.L. Grines, K.R. Karsch, N.S. Kleiman, D.J. Moliterno Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus Am Heart J 144 2002 615 624
15. G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, D. Thomas Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin Circulation 110 2004 392 398
16. G.V.R. Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1969 927 929
17. D.J. Kereiakes, T.M. Broderick, E.M. Roth, D. Whang, T. Shimshak, J.P. Runyon, C. Hattemer, J. Schneider, P. Lacock, M. Mueller, C.W. Abbottsmith Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients undergoing percutaneous coronary intervention Am J Cardiol 84 1999 391 395
18. W.B. Batchelor, T.R. Tolleson, Y. Huang, R.L. Larsen, R.M. Mantell, P. Dillard, M. Davidian, D. Zhang, W.J. Cantor, M.H. Sketch Jr Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the Compare trial Circulation 106; 2002 1470 1476
19. 2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494
20. J.E. Tcheng, J.D. Talley, J.C. O'Shea, I.C. Gilchrist, N.S. Kleiman, C.L. Grines, C.J. Davidson, A.M. Lincoff, R.M. Califf, L.K. Jennings Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study) Am J Cardiol 88 2001 88:1097-1102
21. N. Lakkis, N. Lakiss, J. Bobek, J. Farmer Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited Catheter Cardiovasc Interv 56 2002 474 477
22. D.J. Schneider, H.C. Herrmann, N. Lakkis, F. Aguirre, Y. Wan, A. Aggarwal, S.S. Kabbani, P.M. DiBattiste Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
23. S.S. Kabbani, A. Aggarwal, E.F. Terrien, P.M. DiBattiste, B.E. Sobel, D.J. Schneider Suboptimal early inhibition of platelets by treatment with tirofiban: implications for coronary interventions Am J Cardiol 89 2002 647 650
24. D. Soffer, I. Moussa, M. Karatepe, K.J. Harjai, J. Boura, S.R. Dixon, C.L. Grines, W.W. O'Neill, G.S. Roubin, J.W. Moses Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris Am J Cardiol 91 2003 872 875
25. J.J. Ferguson, E.M. Antman, E.R. Bates, M. Cohen, N.R. Every, R.A. Harrington, C.J. Pepine, P. Theroux The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE 3) study Am Heart J 146 2003 628 634
26. D.J. Kereiakes, N.S. Kleiman, E. Fry, G. Mwawasi, R. Lengerich, K. Maresh, M.L. Burkert, J.W. Aquilina, M. Deloof, T.M. Broderick, T.M. Shimshak Dalteparin in combination with abciximab during percutaneous coronary intervention Am Heart J 141 2001 348 352
27. J.J. Ferguson, R.M. Califf, E.M. Antman, M. Cohen, C.L. Grines, S. Goodman, D.J. Kereiakes, A. Langer, K.W. Mahaffey, C.C. Nessel SYNERGY Trial Investigators Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
28. D.L. Bhatt, B.I. Lee, P.J. Casterella, M. Pulsipher, M. Rogers, M. Cohen, V.E. Corrigan, T.J. Ryan, J.A. Breall, J.A. Moses Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention J Am Coll Cardiol 41 2003 20 25
29. R. Choussat, G. Montalescot, J.P. Collet, E. Vicaut, A. Ankri, V. Gallois, G. Drobinski, I. Sotirov, D. Thomas A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention J Am Coll Cardiol 40 2002 1943 1950